36,749 Shares in Hims & Hers Health, Inc. (NYSE:HIMS) Bought by Genesee Capital Advisors LLC

Genesee Capital Advisors LLC purchased a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 36,749 shares of the company’s stock, valued at approximately $889,000.

A number of other large investors have also added to or reduced their stakes in the business. Perigon Wealth Management LLC bought a new position in shares of Hims & Hers Health during the 4th quarter valued at approximately $337,000. Pacer Advisors Inc. bought a new position in shares of Hims & Hers Health during the 4th quarter worth $374,000. KBC Group NV increased its stake in shares of Hims & Hers Health by 107.9% in the fourth quarter. KBC Group NV now owns 8,471 shares of the company’s stock worth $205,000 after purchasing an additional 4,396 shares in the last quarter. Raleigh Capital Management Inc. boosted its holdings in shares of Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after acquiring an additional 1,100 shares during the period. Finally, SG Americas Securities LLC boosted its holdings in Hims & Hers Health by 44.0% in the 4th quarter. SG Americas Securities LLC now owns 104,422 shares of the company’s stock valued at $2,525,000 after purchasing an additional 31,915 shares during the period. Institutional investors own 63.52% of the company’s stock.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $20.88, for a total transaction of $3,943,981.44. Following the transaction, the chief executive officer now owns 67,015 shares of the company’s stock, valued at $1,399,273.20. The trade was a 73.81 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Patrick Harrison Carroll sold 15,000 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $22.07, for a total transaction of $331,050.00. Following the sale, the insider now owns 196,941 shares in the company, valued at approximately $4,346,487.87. The trade was a 7.08 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,256,067 shares of company stock worth $34,459,485 over the last quarter. Company insiders own 17.71% of the company’s stock.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $31.46 on Wednesday. Hims & Hers Health, Inc. has a 52-week low of $8.51 and a 52-week high of $35.02. The company has a market cap of $6.87 billion, a PE ratio of 71.49 and a beta of 1.31. The firm’s 50 day moving average price is $28.57 and its 200-day moving average price is $22.33.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. During the same period last year, the business posted ($0.04) EPS. The company’s revenue was up 77.1% compared to the same quarter last year. On average, analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on HIMS. Citigroup cut shares of Hims & Hers Health from a “neutral” rating to a “sell” rating and raised their price objective for the company from $24.00 to $25.00 in a research report on Friday, January 10th. Needham & Company LLC boosted their target price on Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Monday, January 6th. TD Cowen reiterated a “buy” rating and issued a $28.00 price target on shares of Hims & Hers Health in a report on Wednesday, November 20th. BTIG Research began coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price objective on the stock. Finally, Canaccord Genuity Group lifted their target price on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $25.13.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.